Stealth BioTherapeutics To Present At Cantor Fitzgerald’s Inaugural Healthcare Conference

BOSTON--(BUSINESS WIRE)--Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced its Chief Executive Officer, Travis Wilson, will present a corporate overview and development update at Cantor Fitzgerald’s Inaugural Healthcare Conference in New York City. The presentation on Wednesday, July 8th at 9:30 AM ET will include the latest clinical results from Stealth’s Bendavia and Ocuvia, investigational drugs that target mitochondrial dysfunction to treat common and rare diseases.

Help employers find you! Check out all the jobs and post your resume.